Items Tagged ‘advanced breast cancer’

December 12, 2017

Kisqali® Improves Outcomes of Premenopausal Women with HR+/HER2- Advanced Breast Cancer

By

It was announced today that results from the Phase III MONALEESA-7 trial evaluating Kisqali® (ribociclib) in combination endocrine-based therapy in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at the 2017 Annual San Antonio Breast Cancer […]

View full entry

Tags: advanced breast cancer, Breast Cancer, cyclin-dependent kinase, inhibitor, kisqali, MONELESSA 7, News, Precision Cancer Medicine, premenopausal, ribociclib, San Antonio Breast Cancer Symposium


November 14, 2017

Kisqali® Improves Outcomes for Premenopausal Women with HR+/HER2- Advanced Breast Cancer

By

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old.1,2 ,3 Historically there younger women were treated the same as their older counterparts, researchers however have more recently begun to focus on improving the treatment outcomes for […]

View full entry

Tags: advanced breast cancer, Breast Cancer, CDK4/6, cyclin-dependent kinase 4 and 6, kisqali, MONALEESA-7, News, Precision Cancer Medicine, ribociclib


October 30, 2017

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer

By

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer progression compared to treatment with fulvestrant alone in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), […]

View full entry

Tags: 4 & 6 inhibitor, abemaciclib, advanced breast cancer, Breast Cancer, CDK, cyclin-dependent kinase, News, Phase 3 MONARCH 2, Precision Cancer Medicine, Verzenio


April 24, 2015

Ibrance®

By

Class: Biological Therapy Generic Name: Palbociclib Trade Name: Ibrance® For which conditions is this drug approved? Ibrance is approved in combination with the medicine Femara® (letrozole) for the treatment of postmenopausal women with advanced breast cancer that is estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative for first therapy. It is also used […]

View full entry

Tags: advanced breast cancer, Biological Therapy, Drug Dictionary, I, Ibrance


April 24, 2015

Palbociclib

By

Class: Biological Therapy Generic Name: palbociclib Trade Name: Ibrance® For which conditions is this drug approved? Ibrance is approved in combination with the medicine Femara® (letrozole) for the treatment of postmenopausal women with advanced breast cancer that is estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative for first therapy. It is also used in […]

View full entry

Tags: advanced breast cancer, Biological Therapy, Drug Dictionary, P, palbociclib